FDA Panel Unanimously Recommends Eli Lilly's Alzheimer's Drug

ToplineA Food and Drug Administration advisory panel unanimously voted Monday to recommend Eli Lilly’s Alzheimer’s drug donanemab for approval, according to multiple outlets, sending the pharmaceutical company’s shares up modestly in after-hours trading and making the treatment’s final approval more likely.The panel voted unanimously for the drug. (AP Photo/Michael Conroy, File)Associated Press Key FactsAll of the panel’s 11 members endorsed donanemab—which data from a clinical trial suggests can slow the p ...